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ATVB IN FOCUS: 
From Cells to the Clinic: Progress in the Development  
of Novel Therapeutics for ATV B Diseases
Advances in Therapies and Imaging for  
Systemic Vasculitis
Tariq E. Farrah, Neil Basu, Marc Dweck, Claudia Calcagno, Zahi A. Fayad, Neeraj Dhaun
ABSTRACT: Vasculitis is a systemic disease characterized by immune-mediated injury of blood vessels. Current treatments 
for vasculitis, such as glucocorticoids and alkylating agents, are associated with significant side effects. Furthermore, the 
management of both small and large vessel vasculitis is challenging because of a lack of robust markers of disease activity. 
Recent research has advanced our understanding of the pathogenesis of both small and large vessel vasculitis, and this has 
led to the development of novel biologic therapies capable of targeting key cytokine and cellular effectors of the inflammatory 
cascade. In parallel, a diverse range of imaging modalities with the potential to monitor vessel inflammation are emerging. 
Continued expansion of combined structural and molecular imaging using positron emission tomography with computed 
tomography or magnetic resonance imaging may soon provide reliable longitudinal tracking of vascular inflammation. In 
addition, the emergence of radiotracers able to assess macrophage activation and immune checkpoint activity represents an 
exciting new frontier in imaging vascular inflammation. In the near future, these advances will allow more precise imaging of 
disease activity enabling clinicians to offer more targeted and individualized patient management.
VISUAL OVERVIEW: An online visual overview is available for this article.
Key Words: antibodies, antineutrophil cytoplasmic ◼ biological products ◼ giant cell arteritis ◼ inflammation ◼ positron emission tomography
Primary systemic vasculitides are an uncommon group of diseases characterized by relapsing and remitting immune-mediated inflammation of blood vessels. They 
affect patients of all ages and pose unique diagnostic and 
therapeutic challenges. Systemic vasculitis can be broadly 
defined by the size of the affected vessels into small ves-
sel vasculitis (SVV), medium vessel vasculitis (MVV), and 
large vessel vasculitis (LVV) with some overlap.1 In LVV, 
the inflammatory response begins at the adventitia and 
spreads inward toward medial and intimal layers.2 This 
results in the development of occlusive and aneurysmal 
vascular lesions. In contrast, small vessel inflammation 
typically begins with endothelial injury and intimal inflam-
mation, which propagates outward to the media and 
adventitia.3 Further spread to the adventitia results in a 
panarteritis, although this is more typical of MVV, which 
shares features of both.4 The early inflammatory injury of 
the intima with subsequent activation of the coagulation 
cascade in small caliber vessels explains the thrombotic 
and necrotizing pathology that characterizes SVV.
Please see www.ahajournals.org/atvb/atvb-focus  
for all articles published in this series.
Although effective, current treatments for systemic vas-
culitis are associated with significant morbidity,5 and sur-
vival remains poor with many patients experiencing chronic 
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relapsing systemic inflammation that contributes to the 
development and progression of cardiovascular disease.6,7 
Indeed, ≈15% of patients experience a major adverse car-
diovascular event within 5 years of diagnosis.6,7 Identifying 
vasculitis early, assessing response to therapy, and detect-
ing disease relapse remain important clinical challenges. 
The last decade has seen major advances in our under-
standing of the pathogenesis of vasculitis. These discover-
ies have led to the development of novel treatments, which 
seek to provide greater efficacy and a more acceptable side 
effect profile. In this review, we discuss the recent advances 
in understanding disease mechanisms of the major vascu-
litides in adults, the consequent development of new treat-
ments, and how existing and novel imaging techniques may 
be used to improve diagnosis and disease monitoring.
LARGE VESSEL VASCULITIS
Clinical Context and Challenges
LVV is the most common primary systemic vasculitis8,9 and 
includes giant cell arteritis (GCA) and Takayasu arteritis (TA). 
The central feature of both is granulomatous arteritis that 
involves the aorta and its major branches.2 GCA exclusively 
affects individuals aged >50 years with a female-to-male 
predominance of 3:1. Additionally, GCA is more common in 
patients of North European descent with an incidence of 20 
to 30 per 100 000 people but is uncommon in Asian ethnic 
groups, incidence ≈1.5 per 100 000.10,11 It typically affects 
the branches of carotid, vertebral, and temporal arteries 
resulting in the classical symptoms of headache, jaw clau-
dication, and loss of vision.1 Large vessel GCA involvement 
is increasingly recognized in up to 70% to 80% of patients 
with GCA and is associated with an increased mortality risk 
related, in part, to aneurysm formation and dissection.12 In 
contrast, TA primarily affects females <50 years of age, 
has a worldwide incidence of ≈0.8 per million, and is rare in 
North Europe but is more common in South East Asia.11,13,14 
TA typically involves the aorta and its primary branches lead-
ing to vascular occlusion with claudication, aneurysm for-
mation, aortic insufficiency, and cardiac failure.1
Nonstandard Abbreviations and Acronyms
ADA2 adenosine deaminase 2
ANCA antineutrophil cytoplasmic antibody
BAFF B-cell activating factor
BlyS B-lymphocyte stimulator
C5aR C5a receptor
CRP C-reactive protein
CT computed tomography
CTA computed tomographic angiography
EGPA  eosinophilic granulomatosis with 
polyangiitis
ET-1 endothelin-1
ETA endothelin-A
ETB endothelin-B
Ga-DOTATATE  gallium-68-labeled 
[1,4,7,10-tetraazacyclododecane-
N,N′,N″,N‴-tetraacetic acid]-D-
Phe1, Tyr3-octreotate
GCA giant cell arteritis
GiACTA giant cell arteritis actemra
GLUT glucose transporter
GPA granulomatosis with polyangiitis
IFN-γ interferon-γ
IL interleukin
LVV large vessel vasculitis
MPO myeloperoxidase
MR magnetic resonance
MRA magnetic resonance angiography
MVV medium vessel vasculitis
PAN polyarteritis nodosa
PD-1 programmed death-1
PD-L1 programmed death ligand-1
PET positron emission tomography
PR3 proteinase-3
SST-2 somatostatin receptor subtype 2
SVV small vessel vasculitis
TA Takayasu’s arteritis
TNFα tumor necrosis factor-α
TSPO translocator protein
VSMC vascular smooth muscle cell
Highlights
• The emergence of novel biologics such as abata-
cept, tocilizumab, and ustekinumab offers more 
precise targeting of the immune response in large 
vessel vasculitis and has shown promise in minimiz-
ing glucocorticoid reliance.
• Novel therapies for B-cell targeting in antineutro-
phil cytoplasmic antibody–associated vasculitis aim 
to build on the success of rituximab. Complement 
blockade has shown promise in preclinical studies 
and recent clinical trials while mepolizumab demon-
strates the key role of interleukin-5 in eosinophilic 
granulomatosis with polyangiitis.
• Multimodal imaging including positron emission 
tomography with computed tomography and mag-
netic resonance has proven utility in diagnosis of 
large vessel vasculitis. The role of positron emis-
sion tomography in tracking disease activity is highly 
promising but needs greater refinement.
• Immuno-positron emission tomography and retinal 
optical coherence tomography may be the next gen-
eration of imaging modalities to offer noninvasive 
assessment and monitoring of systemic vasculitis.
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LVV is a chronic, relapsing disease with ≈80% of 
patients with GCA15 and ≈50% of patients with TA16 expe-
riencing a relapse within 5 years of diagnosis. Current 
treatment is heavily reliant on prolonged use of gluco-
corticoids, which is associated with infections, osteopo-
rotic fractures, hypertension, weight gain, and diabetes 
mellitus.17 The limited success of steroid-sparing agents 
such as methotrexate18 and azathioprine19 in clinical tri-
als of GCA has reinforced this dependence. In contrast 
to SVV, LVV lacks validated markers of disease activ-
ity to guide immunosuppression and detect subclinical 
progressive disease. This chronic, relapsing low-grade 
systemic inflammation contributes to the development of 
cardiovascular disease, which is a major source of mor-
bidity and mortality.6,20,21
Novel Mechanisms, Novel Treatments
Targeting Leucocyte-Cytokine Signatures in LVV
Vascular inflammation in LVV is characterized by 2 distinct 
leucocyte-cytokine signatures (Figure 1). The IL (inter-
leukin)-6/Th17 cell/IL-17 signature is a key mediator of 
Figure 1. Targeting key mechanisms in the pathogenesis of large vessel vasculitis (LVV).  
Cross-sectional diagram of a large vessel depicting important pathogenic pathways of vasculitis. Upper left shows vessel structure in health; 
upper right shows the IL (interleukin)-6/Th17 cell/IL-17 pathway; lower right shows IL-12/Th1 cell/IFNγ (interferon-γ) pathway; lower 
left shows the ET-1 (endothelin-1) system. Adventitial dendritic cells are activated by an as yet unknown trigger, leading to monocyte, CD4+ 
(cluster of differentiation), and CD8+ T-cell infiltration via the vasa vasorum. Cellular infiltration stimulates the release of several proinflammatory 
cytokines including IL-6 and IL-12. IL-6 induces CD4+ T-cell differentiation toward a Th17 phenotype. These Th17 cells secrete IL-17, which 
in turn recruits monocytes and neutrophils to the inflamed medial layer. The ensuing florid inflammatory response spreads from the adventitia 
toward the intima with giant cell formation. Glucocorticoids can effectively suppress this pathway, but more precise targeting of IL-6 is possible 
by the monoclonal antibody tocilizumab. In parallel, IL-12 promotes polarization of CD4+ to a Th1-IFNγ secreting phenotype. IFNγ release 
orchestrates macrophage recruitment and granuloma formation, as well as triggering pathways that lead to proliferation and inward migration 
of vascular smooth muscle cells (VSMCs). This pathway is resistant to suppression by glucocorticoids but can be inhibited by ustekinumab. 
The widespread uncontrolled T-cell activation can be targeted by abatacept, which blocks T-cell interaction with antigen presenting cells. The 
inflammatory milieu within the vessel wall causes upregulation of ET-1 at the protein level and increased VSMC ET receptor expression. ET-1 
promotes VSMC proliferation and migration that in combination with the effects of IFNγ results in intimal hyperplasia and luminal stenosis 
characteristic of LVV. In vitro data suggest this may be ameliorated by ET receptor antagonism.
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the early inflammatory response within the vessel wall 
and is glucocorticoid sensitive. A separate IL-12/Th1 
cell/IFN-γ (interferon-γ) pathway promotes sustained 
granulomatous inflammation and vascular smooth mus-
cle cell (VSMC) proliferation and appears glucocorticoid 
resistant in GCA.22
These concepts are supported by clinical studies show-
ing elevated circulating IL-6, IL-12, and IL-1723 during 
active GCA alongside increased Th17/IL-17 and Th1/IFNγ 
expression in culprit lesions on temporal artery biopsy.24,25 
Following glucocorticoid treatment, circulating IL-6 and 
IL-17, as well as vessel Th17/IL-17 expression, fall mir-
roring clinical improvement.20 However, circulating IL-12 
concentrations and tissue Th1/IFNγ expression remain 
unchanged.24 Relative tissue expression of these leucocyte-
cytokine signatures may influence outcomes as greater cul-
prit lesion expression of IL-17 has been shown to predict an 
earlier response to glucocorticoids, likelihood of glucocorti-
coid discontinuation, and a lower risk of relapse.25 Extrapo-
lating these concepts to TA should be done with caution as 
recent data show that, despite similar cytokine signatures, 
glucocorticoids had little effect on IL-17 but suppressed 
IFNγ.26 Reasons for this are unclear but may be because 
of differences in typical affected age group, ethnicity, and 
genetic associations between TA and GCA.
Targeting IL-6
IL-6 is a potent mediator of the inflammatory response 
in both the vessel wall and the systemic circulation. 
Tocilizumab is a humanized monoclonal antibody that 
competitively inhibits IL-6 by binding to circulating and 
membrane-bound IL-6 receptors. The first study of 
tocilizumab in GCA was published in 2016. This single- 
center, randomized, placebo-controlled double-blind study 
enrolled 30 patients, most with new-onset GCA.27 Patients 
received monthly tocilizumab or placebo alongside tapered 
glucocorticoids. The primary outcome of complete remis-
sion by 12 weeks was achieved by 17 (85%) patients in 
the tocilizumab arm compared with 4 (40%) patients in 
the placebo arm. Tocilizumab was also associated with a 
greater relapse-free survival at 1 year, longer time to first 
relapse and lower cumulative glucocorticoid dose. Adverse 
advents were similar between arms.
These findings were extended by the phase 3 
GiACTA trial (Giant Cell Arteritis Actemra) that enrolled 
251 patients with new-onset, relapsing, or refractory 
GCA.28 Randomization was to one of tocilizumab weekly 
plus 26-week glucocorticoid taper, tocilizumab every 2 
weeks plus 26-week glucocorticoid taper, placebo plus 
26-week glucocorticoid taper, or placebo plus 52-week 
glucocorticoid taper. The primary outcome of sustained 
remission at 52 weeks was met by >50% of patients 
in the tocilizumab arms demonstrating superiority to pla-
cebo (≈15%).28 Tocilizumab was also associated with 
lower rates of disease flares, longer time to flare, and 
a lower cumulative glucocorticoid dose. There was no 
difference in total adverse events across the 4 groups, 
and the highest number of serious adverse events 
occurred in the slow glucocorticoid taper group.29
The compelling evidence from these trials led to the 
approval of tocilizumab for GCA by the Food and Drug 
Administration in the United States last year and the 
National Institute for Health and Care Excellence in 
the United Kingdom this year. The optimal duration of 
treatment is unclear. This is important given the costs 
of tocilizumab are ≈$18 000 (≈£12 000) per patient-
year. Importantly, from a therapeutic perspective, ≈50% 
of patients receiving tocilizumab in GiACTA failed to 
achieve sustained remission at 1 year suggesting that 
targeting IL-6 alone might be insufficient for adequate 
disease control in some patients.28
A key effect of IL-6 production is the induction of 
CRP (C-reactive protein) transcription, which drives the 
systemic inflammatory response and associated symp-
toms.30 Consequently, tocilizumab’s inhibition of IL-6 
leads to a rapid suppression of circulating CRP, which 
results in significant symptomatic improvement. This 
renders CRP ineffective as a marker of disease activ-
ity and has raised concerns that tocilizumab may mask 
ongoing inflammation at the level of the vessel wall. 
These concerns are supported by clinical trial data. In 
the GiACTA trial, one patient developed arteritic isch-
emic optic neuropathy while receiving tocilizumab,28 and 
a recent imaging substudy of the first tocilizumab trial by 
Villiger et al27 reported that one-third of patients in the 
tocilizumab arm (n=3) had persisting or increased mural 
contrast enhancement on magnetic resonance angiog-
raphy (MRA) despite clinical remission.31 Larger studies 
particularly with concurrent serial multimodal imaging 
may help clarify these concerns.
In TA, the first randomized, double-blind, placebo-con-
trolled trial of tocilizumab was published in late 2017.32 
Thirty-six patients aged >12 years with relapsing TA 
received high-dose glucocorticoids to induce remis-
sion before randomization to either tocilizumab or pla-
cebo given weekly alongside a tapering glucocorticoid 
dose. Intention-to-treat analysis failed to demonstrate a 
clear difference in primary outcomes of time to relapse 
(P=0.056). The per-protocol analysis did suggest a 
longer time to relapse in patients receiving tocilizumab 
(P=0.03) with no increased risk of infections or other 
serious adverse effects. Further studies are needed to 
define the role of IL-6 inhibition in TA.
Targeting IL-12 and IL-23
IL-12 and IL-23 induce the polarization of T cells toward 
INFγ (interferon-gamma) secreting Th1 cells and IL-17 
secreting Th17 cells, respectively (Figure 1).22 IL-12 and 
IL-23 share a P40 subunit that can be targeted by the 
novel monoclonal antibody, ustekinumab. Ustekinumab 
is licensed for use in psoriasis, psoriatic arthritis, and 
Crohn colitis,33,34 and data in LVV are emerging. A recent 
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open-label trial recruited 25 patients with refractory GCA 
and administered ustekinumab at baseline, 1 month, and 
then 3 months for up to a year.35 Ustekinumab allowed sig-
nificant reductions in glucocorticoid dose from a median of 
20 to 5 mg, and ≈25% of patients were able to stop glu-
cocorticoids completely within the 12 months after enroll-
ment. Interestingly, in patients who underwent computed 
tomographic (CT) angiography (CTA) before and after 
(n=8), all showed an improvement in mural thickness with 
complete resolution seen in 4 patients.35 Whether these 
radiological changes occur because of specific inhibition of 
Th1/INFγ -mediated VSMC proliferation by ustekinumab 
or simply by reducing vessel inflammation overall needs 
clarification. Further randomized trials are now awaited.
Targeting T-Cell Activation
Uncontrolled T-cell activation is a central feature of the 
inflammatory response in LVV. Abatacept is a fusion pro-
tein that inhibits the interaction between CD28 (clus-
ter of differentiation) on T cells and CD80 or CD86 on 
antigen-presenting cells and thus prevents T-cell activa-
tion.36 The clinical benefit of targeting this pathway has 
recently been assessed by 2 separate randomized con-
trolled trials, one in GCA37 and the other in TA,38 with con-
trasting results. Both trials had a similar design in which 
all enrolled patients received abatacept over 8 weeks to 
induce disease remission. Those who achieved remission 
at 12 weeks after enrollment were randomized 1:1 to 
either monthly abatacept or placebo. All patients received 
tapering glucocorticoids from entry, and the primary end 
point was relapse-free survival at 12 months.37,38
In the GCA trial, 41 of 49 (83%) enrolled patients 
were randomized (ie, achieved remission with abatacept), 
and relapse-free survival was 48% with abatacept as 
maintenance therapy compared with 31% with placebo 
(P=0.049).37 Patients in the abatacept arm spent ≈10 
months in remission compared with ≈4 months with pla-
cebo, and there were no differences in infection rates or 
prednisolone exposure before relapse.37 However, in the 
TA trial, the first ever Randomized Controlled Trial in TA, 
fewer patients were randomized (26 of 34; 74%), and 
no difference in relapse-free survival at 12 months was 
seen between abatacept and placebo (22% versus 40%, 
respectively).38 These data provide further support that 
GCA and TA are distinct, as suggested by their differ-
ential geoepidemiology, cytokine profiles, and TA-specific 
genetic associations.39 It is worth noting that in the GCA 
trial ≈50% of patients randomized were new presentations 
spread equally between treatment arms.37 In the TA trial, 
all patients randomized to abatacept had relapsing dis-
ease and median disease duration of >5 years compared 
with <1 year in the placebo arm.38 Thus, this group likely 
had difficult-to-control disease and was prone to relapse, 
which may have influenced achievement of the primary 
outcome. Regardless, these trials indicate a potential role 
for abatacept in LVV that warrants additional study.
Imaging of LVV
The diagnosis of GCA often involves tissue biopsy, and 
performing an interval biopsy to assess disease activity is 
not feasible. In large vessel GCA and TA, obtaining tissue 
for diagnosis is frequently impossible. Commonly used 
circulating measures of disease activity such as CRP and 
erythrocyte sedimentation rate normalize rapidly after 
commencement of treatment,40 despite ongoing inflam-
mation at the level of the vessel41 and can remain within 
normal limits even when disease relapses.42 Furthermore 
LVV lacks a validated marker of disease activity such as 
the Birmingham Vasculitis Activity Score in antineutrophil 
cytoplasmic antibody (ANCA)–associated vasculitis. The 
potential to visualize and track large vessel inflammation 
using imaging, therefore, represents an exciting break-
through in LVV and may yield critical biomarkers of dis-
ease activity to guide treatment. In recognition of this, the 
European League Against Rheumatism released guid-
ance for clinicians on the use of imaging in LVV includ-
ing technical and operational parameters for ultrasound, 
CT, magnetic resonance imaging, and positron emis-
sion tomography (PET).43 This guidance also details an 
extensive future research agenda demonstrating a clear 
intent to harness the power of multimodal imaging to 
improve patient outcomes. Table 1 summarizes the cur-
rent modalities utilized in imaging LVV.
Structural Imaging
Ultrasound
Color doppler ultrasound of the temporal arteries in 
suspected cranial GCA is a safe, rapidly available, cost-
effective technique for diagnosis and is recommended 
as the primary imaging modality of choice by European 
League Against Rheumatism.43 Detection of homog-
enous hypoechoic mural thickening, the halo sign, has 
a reported pooled sensitivity and specificity of 77% and 
96%, respectively, which rises to 100% specificity if pres-
ent bilaterally or persists despite luminal compression.43 
However, a recent multicenter study of 381 patients with 
suspected GCA reported a much lower sensitivity of 54% 
with ultrasound, but this still compared favorably to that 
of temporal artery biopsy (39%).45 The use of sonogra-
phers with less experience may have contributed to the 
observed lower sensitivity of ultrasound and highlights 
its operator-dependent limitations. Although ultrasound 
cannot reliably assess aortic involvement in LVV, it can 
identify axillary and femoral vasculitis.46,47 Assessment of 
the axillary arteries is particularly useful for diagnosis as 
they are not commonly affected by atherosclerosis com-
pared with lower limb vessels, which can affect the utility 
of femoral vessel assessment.48 The role of ultrasound in 
disease monitoring is unclear as time to regression of the 
halo sign after starting treatment is highly variable and 
halo signs around larger vessels may persist for months 
to years.48
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CT Angiography
CTA provides a structural assessment of extracranial 
and aortic vessels. It can report the extent of LVV and 
delineate mural thickening, luminal stenosis (Figure 2), 
and aneurysmal dilation, as well as mural contrast 
enhancement (assumed to represent active vasculi-
tis).44 Thus, CTA may be able to monitor development 
of vascular complications in patients with LVV, such 
as aortic aneurysms. Prospective data supporting the 
role of CTA for diagnosis of LVV are few but show evi-
dence of large vessel involvement in ≈70% of patients 
with biopsy-proven, active GCA.49,50 Data on tracking 
disease activity with CTA are equally scarce but have 
reported persistent mural thickening on follow-up imag-
ing in two-thirds of patients with biopsy-proven GCA 
despite clinical and biochemical remission.51 However, 
nearly all patients had resolution of mural contrast 
enhancement on repeat CTA,51 suggesting that current 
CTA-derived metrics may be too coarse to reliably track 
disease. The high effective radiation dose of CTA limits 
its use in young patients and for serial imaging, but 
evidence supporting the safety of low-dose CT proto-
cols may change this.52 This is important in practical 
terms as CT is more widely accessible than magnetic 
resonance (MR). Regardless, the use of iodinated con-
trast carries the risks of allergic reactions as well as 
contrast-related kidney dysfunction.
MR With or Without Angiography
MR with or without angiography provides superior soft 
tissue contrast compared with CTA, avoids exposure to 
ionizing radiation (Figure 3), and is the recommended 
modality for diagnosis of suspected TA given the 
younger age of affected patients.43 High-resolution MR 
of cranial vessels has a similar sensitivity and speci-
ficity to ultrasound for the diagnosis of cranial GCA 
and thus is recommended if ultrasound is inconclusive 
or unavailable.43 After contrast administration, mural 
enhancement on T1-weighted images is suggestive 
of active vessel inflammation. Suppression of signals 
from both adipose tissue (by fat saturation or short T1 
inversion recovery sequences) and blood flow (black-
blood sequences) enhances visualization of mural 
contrast uptake particularly in the carotid, subclavian, 
and axillary arteries, which lie close to subcutaneous 
and fascial fat. T2-weighted images can demonstrate 
mural edema indicative of vasculitis but are considered 
by European League Against Rheumatism to be less 
sensitive and prone to artifact.43 MRA can also assess 
the wider vasculature to define disease extent and is, 
therefore, attractive for the longitudinal monitoring of 
vessel structure. A recent study of both patients with 
GCA and TA at various stages of their disease found 
that MRA provided better evaluation of disease extent 
compared with PET but correlated poorly with clinical 
and circulating measures of disease activity.53 Gluco-
corticoids and biologic therapy can modify mural edema 
and enhancement on MRA,54 but the heterogenous 
nature of the study population in terms of age, disease 
type, and duration may explain the observed discor-
dance between imaging and clinical assessment.53 A 
further strength of MR imaging is that specific cardiac 
sequences can be readily integrated alongside vascu-
lar imaging, which is particularly relevant for TA. This 
approach has been shown to be feasible55 and can pro-
vide assessments of left ventricular volume, ejection 
Table 1. Multimodal Imaging of Large Vessel Vasculitis
Modality
Diagnostic 
Role Sensitivity Specificity Key Imaging Features
Disease  
Activity Role Strengths Weaknesses
US + 77% 96% Halo sign ± Accessible; cost-effective Operator dependent; 
unable to detect 
aortic disease
Cranial 
MRI
+ 73%–93% 81%–88% Mural thickening; contrast 
enhancement
ND Operator independent Expensive; unable 
to detect LV-GCA; 
patients with MR-
incompatible devices
CTA + GCA, 73%*; 
TA, 100%*
GCA, 78%*; 
TA, 100%*
Stenosis; aneurysm 
dilation; mural 
thickening±enhancement
± Assess burden; detect 
complications
Radiation exposure; 
iodinated contrast 
load
MRA + GCA, ND; 
TA, 100%*
GCA, ND; TA, 
100%*
Stenosis; aneurysmal 
dilation; mural 
thickening±enhancement
± Assess burden; detect 
complications; no radiation 
exposure; integrated cardiac 
images
Less accessible; 
expensive
PET + GCA, 76%–
90%; TA, 
70%–87%
GCA, 89%–
98%; TA, 
73%–84%
Increased mural tracer 
uptake
± Assess burden and activity; 
combined with CT/MR 
for hybrid structural and 
functional imaging
Radiation exposure; 
current tracers lack 
specificity
Sensitivity and specificity values are pooled from available studies reviewed in references.43,44 CT indicates computed tomography; CTA, computed tomography 
angiography; GCA, giant cell arteritis; LV-GCA, large vessel giant cell arteritis; MR, magnetic resonance; MRA, magnetic resonance angiography; MRI, magnetic 
resonance imaging; ND, no data; PET, positron emission tomography; TA, Takayasu arteritis; and US, ultrasound.
*Data derived from a single study.
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fraction, aortic root dilation, and myocardial scarring 
alongside standard assessments of vasculitis disease 
activity and burden.55 Such data may identify patients 
at high risk of poor outcomes who might benefit from 
targeted intervention, but this requires evaluation in 
large studies. Limitations of MR include its availabil-
ity, cost, and patient tolerability, particularly if multiple 
vessel beds are imaged. Lack of availability may limit 
its use in GCA where rapid diagnosis and therapy are 
essential to avoid irreversible visual loss.
An important limitation of both CTA and MRA is a 
lack of standardized imaging-based outcome measures 
for disease burden and activity. Both European League 
Against Rheumatism and the Outcome Measures Rheu-
matology groups have highlighted the urgent need for 
such measures for use in clinical trials.43,57 A recent 
study designed a cross-platform angiographic scoring 
system applicable to both CTA and MRA images.58 This 
was then validated in a cross-sectional and longitudinal 
study of 131 patients (96 with TA, 35 with GCA), and 
scoring correlated well with disease burden at baseline, 
subsequent disease activity, and progression of vascular 
lesions.58 External validation in larger prospective studies 
is required to examine the utility of this system further.
Molecular Imaging
Positron Emission Tomography
Both CTA and MRA provide detailed structural assess-
ments of vessel inflammation, but treatment decisions 
are primarily influenced by disease activity—a functional 
metric. PET is a highly sensitive molecular imaging tech-
nique that employs radiotracers to measure the activity 
of metabolic processes in vivo. 18F-fluorodeoxyglucose 
(18F-FDG) is a glucose analogue that contains an 18- 
fluoride group in place of a hydroxyl group. After uptake 
into cells by GLUT (glucose transporter) proteins, 18F-
FDG undergoes phosphorylation by hexokinase; however, 
the 18-fluoride group prevents entry into downstream 
Figure 2. Computed tomography (CT) angiography in large 
vessel vasculitis (LVV).  
Coronal oblique multiplanar reconstruction contrast-enhanced CT 
with angiography demonstrating diffuse mural thickening of the 
thoracic and abdominal aorta (Ao; red asterisks) in a patient with 
LVV. AoR indicates aortic root; LA, left atrium; PA, pulmonary artery; 
and RV, right ventricle.
Figure 3. 18F-fluorodeoxyglucose (18F-FDG) positron emission tomography (PET)–magnetic resonance (MR) in large vessel 
vasculitis.  
A, Cardiac MR image with black-blood sequence in the sagittal plane demonstrating circumferential mural thickening of AoR (aortic root) and 
ascending Ao (aorta; red asterisks). B, Same MR sequence fused with 18F-FDG PET showing diffuse homogenous FDG uptake along the 
length of ascending Ao in keeping with severe active vasculitis. LA indicates left atrium; and PA, pulmonary artery. Adapted from Tarkin et al56 
with permission. Copyright © 2016, the Authors.
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metabolic pathways. Reconversion of phosphorylated 
18F-FDG by glucose-6-phosphatase is slow, and the end 
product is unable to exit the cell because of its negative 
charge.59 Consequently, 18F-FDG is trapped intracellularly 
undergoing emission decay that is detected by scintigra-
phy. Thus, 18F-FDG reports cellular glucose utilization as 
a marker of cellular metabolic activity.59
Cells with high glycolytic activity show greater 18F-
FDG uptake because of greater GLUT expression.59 
Macrophages, monocytes, and lymphocytes have all 
been shown to upregulate GLUT-1, GLUT-3, and 
GLUT-5 expression in response to inflammatory stim-
uli, represented by avid 18F-FDG uptake in inflamed 
tissues.60–62 18F-FDG PET has been widely used to 
study atherosclerotic inflammation where the intensity 
of tracer uptake reflects plaque macrophage burden.63 
These properties provide a biological rationale for 18F-
FDG PET imaging in vasculitis.63 PET involves around 
50% of the effective radiation of a diagnostic CT but is 
often combined with low-dose attenuation correction CT 
or MR to provide precise anatomic localization of tracer 
uptake (Figure 4).43
PET in LVV
18F-FDG is the most widely studied PET radiotracer with 
prospective data supporting its utility in the diagnosis of 
LVV.64–69 A recent meta-analysis of predominantly pro-
spective studies totaling 170 patients reported a pooled 
sensitivity of 76% and specificity of 93% of 18F-FDG 
PET for diagnosing LVV.70
There are few data with respect to tracking disease 
activity longitudinally. Blockmans et al71 studied 35 
patients with GCA who had a temporal artery biopsy 
followed by a baseline 18F-FDG PET before treatment 
and then the scan was repeated at 3 and 6 months. 18F-
FDG uptake fell significantly at 3 months compared with 
baseline, but ongoing vessel uptake persisted in >50% 
of patients at 6 months despite clinical and biochemi-
cal remission.71 Grayson et al72 recruited 56 patients 
with LVV (30 GCA, 26 TA) and 59 comparator subjects 
(35 with hyperlipidemia, thus more likely to have aortic 
atherosclerosis; 17 LVV mimics and 9 healthy controls). 
Thirty-five patients with LVV had a follow-up PET scan 
with a mean interval of ≈6 months. Qualitative 18F-FDG 
uptake was significantly greater in patients with LVV 
compared with comparator subjects and in active dis-
ease compared with remission. In addition, greater global 
18F-FDG uptake while in clinical remission was predic-
tive of future relapse.72 Importantly, 17% of patients in 
the comparator group had 18F-FDG uptake qualitatively 
interpreted as active vasculitis, highlighting the limita-
tions of this tracer as specific marker of disease activity 
in LVV. Similar limitations have been encountered in TA 
where patients with prosthetic vascular grafts demon-
strated increased 18F-FDG uptake in grafts on PET-CT 
despite clinical or biochemical remission and no evidence 
of graft infection.73 Follow-up PET imaging (n=9) ≈15 
months later showed no change in graft 18F-FDG uptake 
despite the use of additional immunosuppression in the 
intervening period.73
The available data show discordance between imag-
ing-reported vessel inflammation and clinical markers of 
disease activity. Whether persisting 18F-FDG uptake or 
mural thickness represents subclinical vasculitis, remod-
eling, or atherosclerosis is unclear and is a critical area 
for further study. Addressing this issue will require hybrid 
imaging modalities, better delineation of mural tracer 
uptake patterns, greater metabolic specificity of tracers, 
Figure 4. Assessing disease activity in large vessel vasculitis (LVV) with positron emission tomography (PET).  
A, Sagittal attenuated corrected 18F-fluorodeoxyglucose (18F-FDG) PET (left) and fused 18F-FDG PET-computed tomography (CT; right) 
images from a patient with active LVV before treatment. Images show diffuse increased FDG uptake in relation to the aortic wall (black and 
white arrows) corresponding to the mural thickening demonstrated on the CT in Figure 3. B, Repeat 18F-FDG PET-CT images obtained after 6 
mo of treatment with glucocorticoids and successful clinical remission demonstrates resolution of the abnormal mural aortic FDG uptake.
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and clearly defined clinical end points. The advent of 
hybrid PET-MR for LVV29 with its superior soft tissue 
contrast and lower radiation exposure for serial imaging 
may be the likeliest platform to help achieve this, but the 
limited available data are conflicting.29,74 The diagnostic 
sensitivity of 18F-FDG PET for active GCA appears pre-
served for ≤3 days after commencing glucocorticoids65 
but falls significantly by 10 days,75 highlighting the par-
ticular challenge of accessibility to novel imaging modali-
ties when prompt treatment is essential.
MEDIUM VESSEL VASCULITIS
Clinical Context and Challenges
Polyarteritis nodosa (PAN) is the predominant MVV in 
adults. Kawasaki disease—the other major form of MVV 
and an acute arteritis of childhood—is discussed else-
where.76 PAN is uncommon with an estimated incidence 
of 1 to 10 per million.77 Both sexes are affected equally, 
and the peak age range of onset is between 40 and 60 
years.78 The etiopathogenesis of PAN is strongly linked 
to viral hepatitis infection, particularly hepatitis B virus,79 
which compromised over one-third of 348 PAN cases in 
the largest case series to date.78 The incidence of hepa-
titis B virus–related PAN has declined substantially over 
the last 4 decades after improvements in immunization, 
transfusion practice, and hepatitis B virus therapy.78,80
PAN can manifest as a systemic vasculitis or a skin-
limited form, cutaneous PAN. Both are characterized by 
a transmural necrotizing arteritis of muscular arteries. 
The most commonly affected sites are the skin (causing 
livedo reticularis and ulceration) and peripheral nerves 
(leading to a mononeuritis multiplex).4 Involvement of 
visceral vessels is also common with multiple irregular 
arterial stenoses and microaneurysms demonstrable 
(Figure 5) on contrast angiography in up to 90% of 
patients81,82 These can occur in any organ but are the 
most frequent in the renal and mesenteric arteries; how-
ever, reliable frequency data are limited by sampling 
bias.78 Renal involvement can lead to segmental renal 
infarction and impaired renal function, as well as hyper-
tension, whereas mesenteric disease manifests as gut 
ischemia, perforation, and hemorrhage from aneurysm 
rupture.78 Despite treatment, mortality may be as high 
as 35% at 5 years in those with severe disease as indi-
cated by the Five Factor Score.78,83
Novel Mechanisms and Potential Treatments
Pathogenesis of PAN
Compared with other vasculitides, the pathogenesis of 
PAN is poorly understood. Endothelial injury, through 
immune complex deposition and viral replication, has 
been proposed as a key trigger in hepatitis B virus–
related PAN.84 This is supported by the success of antiviral 
therapy and plasma exchange in achieving sustained 
remission but does not explain the residual majority of 
PAN, which is noninfection related. In these cases, long-
term immunosuppression with glucocorticoids alongside 
other agents such as cyclophosphamide, methotrexate, 
or azathioprine improves patient outcomes and supports 
an autoimmune component to pathogenesis.85 However, 
relapse rates can reach 50% at 2 years, and these drugs 
have significant side effects.78
T-Cell Activation and ADA2 in PAN
Recent studies exploring immunopathogenesis have 
found higher IFN-γ expression in CD4+ T cells in 
patients with PAN compared with patients with granu-
lomatosis with polyangiitis (GPA) but noticeably lower 
IL-17 expression.86 IFN-γ is a potent inhibitor of regula-
tory T-cell function, and this same study found significant 
impairment in the immunosuppressive potential of regu-
latory T cells isolated from patients with PAN compared 
with those isolated from healthy controls.86 The relative 
lack of IL-17 expression seen in this study may partly 
explain the absence of granulomata in PAN, compared 
with LVV where IL-17 (from Th17 cells) and IFN-γ (from 
Th1 cells) synergistically lead to granuloma formation.22 
Blocking T-cell activation in PAN using TNFα (tumor 
necrosis factor-α) blockers or tociluzumab has shown 
some promise in limited case series.87–89
The identification of a potential genetic basis for PAN 
has provided novel perspective into pathogenesis and 
renewed interest in the potential role of TNFα block-
ade. Whole-exosome and candidate gene sequencing of 
patients with familial PAN and PAN-like syndromes and 
unaffected family members has identified several novel 
loss-of-function homozygous or compound heterozygous 
mutations of genes encoding ADA2 (adenosine deami-
nase 2), formerly known as cat eye syndrome CECR1 
gene.90,91 The predominant site of ADA2 expression is 
in myeloid cells, which export ADA2 into the extracel-
lular compartment.92 In vitro data have shown that ADA2 
drives monocyte differentiation and proliferation of mac-
rophages and CD4+ T cells92 and that ADA2 knockout 
skews monocyte polarization toward an inflammatory 
M1 phenotype with subsequent disruption of endothe-
lial layer integrity.90 Thus, deficiency of ADA2 may initiate 
a vicious cycle of inflammation and vascular disruption 
that manifests as a systemic medium vasculopathy with 
the clinical and histopathologic features of PAN. Indeed, 
many patients with deficiency of ADA2 syndromes fit the 
diagnostic criteria for PAN.
The vasculopathy associated with loss of ADA2 typi-
cally presents in childhood, but adult presentations have 
also been reported.90,91,93,94 Across various series, these 
patients show variable responses to standard treatments 
for PAN. In the largest European study, glucocorticoids 
while initially effective were associated with relapse on 
tapering.94 Other treatments such as cyclophosphamide, 
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methotrexate, and azathioprine were ineffective at con-
trolling disease during steroid taper.94 However, in both 
European94 and ultrasound91 series, TNFα blockade 
has shown consistent efficacy in suppressing vasculitis, 
although what constitutes response was not clearly or 
uniformly defined. This efficacy extended to patients with 
life-threatening disease despite maximal tolerated doses 
of cyclophosphamide.91
Why TNFα blockade is particularly effective in defi-
ciency of ADA2 vasculopathy is unclear. Skin biopsies 
from these patients show a necrotizing, nongranuloma-
tous MVV with abundant staining for TNFα,90 but further 
work is needed to clarify the precise mechanisms. The 
relevance of ADA2 to all forms of PAN is also unclear. 
ADA2 activity appears important in the immune response 
to infections, particularly intracellular pathogens.95 It is 
possible that more subtle impairments of ADA2 could be 
induced or exacerbated by intracellular infection thereby 
promoting immune dysregulation and vascular injury. 
Assessing ADA2 gene expression in all patients present-
ing with PAN is potentially feasible given its low inci-
dence and may reveal a novel pathway of pathogenesis.
Imaging in PAN
Structural and Molecular Imaging
Microaneurysms or arterial stenoses are present in a 
majority of patients with PAN at presentation.78,81,82 Fluo-
roscopic-guided contrast angiography is considered the 
optimal modality for identifying these abnormalities with 
Figure 5. Computed tomography angiography (CTA) in polyarteritis nodosa.  
A, Coronal maximum intensity projection CTA demonstrating bilateral intrarenal microaneurysms (white arrows) and a large right subcapsular 
perinephric hematoma (red arrow). B, Repeat CTA 6 mo later following immunosuppressive treatment and achievement of clinical remission 
shows resolution of radiological changes.
D
ow
nloaded from
 http://ahajournals.org by on August 6, 2019
AT
VB
 IN
 F
OC
US
 - 
VB
Farrah et al Novel Management of Vasculitis
August 2019 Arterioscler Thromb Vasc Biol. 2019;39:1520–1541. DOI: 10.1161/ATVBAHA.118.3109571530
a reported sensitivity and specificity of ≈90%.96 However, 
this carries the risks associated with arterial cannulation 
including bleeding, embolization, and pseudoaneurysm 
formation in addition to risks of contrast administration 
such as allergic reactions and renal dysfunction. CTA and 
MRA provide a noninvasive assessment of but may be 
less sensitive for the detection of microaneurysms (typi-
cally 1 to 5 mm in size).97 Although 18F-FDG PET has 
been used in small studies of PAN, showing increased 
uptake in medium arteries,98 its use has not been ade-
quately assessed.
Similar to LVV, assessment of disease activity is chal-
lenging in PAN. The vast majority of imaging data in PAN 
relate to diagnosis with fluoroscopic contrast angiogra-
phy. Data for CTA and MRA are limited to individual case 
reports and case series with CTA and MRA. However, 
interval imaging across all 3 modalities shows resolu-
tion of microaneurysms with disease remission99,100 
(Figure 5) and progression of lesions with refractory dis-
ease,101 thus may provide useful additional information 
on top of standard clinical and biochemical parameters. 
The lack of ionizing radiation makes MRA an attrac-
tive modality for future longitudinal studies to track dis-
ease activity. Hybrid PET/MR imaging may enable more 
refined tracking of disease activity particularly in patients 
with visceral vessel lesions that are at high risk of cata-
strophic complications.
SMALL VESSEL VASCULITIS
Clinical Context and Challenges
ANCA-associated vasculitis is the commonest systemic 
SVV in adults and has an incidence of 20 to 30 per 
million population.102 It is characterized by necrotizing 
inflammation of small arteries, arterioles, and capillar-
ies, usually in the presence of autoantibodies directed 
against the neutrophil cytoplasmic granular proteins 
PR3 (proteinase-3) and MPO (myeloperoxidase),1 
although ≈10% patients with the characteristic clinical 
and histological features of ANCA-associated vasculitis 
lack measurable circulating ANCA.103 The peak age of 
onset of ANCA-associated vasculitis is in the fifth and 
sixth decade with no clear sex predominance.102 There 
are 3 clinical subtypes, GPA, microscopic polyangiitis, 
and eosinophilic GPA (EGPA); the key features of these 
are described in Table 2. From a clinical perspective, it 
is noteworthy that significant overlap between clinical 
subtypes exists.1 More recently, focus has shifted to 
classification by ANCA subtype after the discovery of 
genetically distinct origins for MPO and PR3 ANCA.104 
These differences may underpin the recognized dif-
ferences in clinical expression of disease105 and have 
future implications for treatment. Overall, however, the 
risk of premature mortality is >2.5× greater than in an 
age- and sex-matched general population.106
Fifty percent of patients with ANCA-associated 
vasculitis experience a relapse within 5 years of diag-
nosis.109 PR3+ disease is frequently associated with 
granulomatous inflammation, as well as higher rates of 
relapse and refractory disease.105 The reasons for this 
are unknown but may relate to their differing genetic 
basis of ANCA subtypes.104 In addition, granulomata 
may act as tertiary lymphoid organs110 and harbor auto-
reactive B cells facilitating their escape from autode-
letion or depletion by cytotoxic treatments. As with 
LVV, persisting low-grade inflammation contributes 
to the development of cardiovascular disease mor-
bidity and mortality.7 Treatment of ANCA-associated 
vasculitis is divided into distinct induction and main-
tenance phases.111 The goal of induction therapy is 
rapid, effective suppression of the immune response 
to limit inflammatory organ injury. Maintenance therapy 
provides lower intensity immunosuppression over the 
medium to long term to prevent disease relapse and 
accrual of organ damage. In both phases, achieving 
effective immunosuppression while minimizing toxic 
side effects is challenging.112 Agents such as cyclo-
phosphamide and rituximab are effective but similarly 
associated with an increased risk of infection and can-
cer.112 Finally, the lack of reliable tools for assessing 
disease activity while on treatment and stratifying the 
risk of future relapse are critical challenges. This makes 
it difficult not only to identify patients with ongoing dis-
ease activity who require treatment escalation but also 
patients who are at low risk of relapse who can safely 
stop potentially toxic immunosuppression.
Table 2. Clinical and Biochemical Features of  
ANCA-Associated Vasculitis Subtypes8,107,108
Features GPA MPA EGPA
Incidence, per 
million per y
5–10 6–8 1–3
ANCA present, % ≈50%–90% ≈90% ≈40%
  Predominant 
subtype
PR3 MPO MPO
ENT involvement +++ + ++
Lung involvement ++ ++ +++
Pulmonary 
hemorrhage
+ ++ −
Kidney involvement ++ +++ +
Nerve involvement + ++ +++
Unique features Orbital disease; 
airway stenosis
Interstitial lung 
changes
Eosinophilia; 
cardiac disease; 
adult-onset 
asthma
ANCA indicates antibody to neutrophil cytoplasmic antigens; EGPA, 
eosinophilic granulomatosis with polyangiitis; ENT, ear, nose, and throat; 
GPA, granulomatosis with polyangiitis; MPA, microscopic polyangiitis; MPO, 
myeloperoxidase; and PR3, proteinase-3.
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Novel Mechanisms and Treatments
B Cells in ANCA-Associated Vasculitis
The introduction of the alkylating agent cyclophos-
phamide 4 decades ago transformed the short-term 
prognosis of ANCA-associated vasculitis.113,114 Cyclo-
phosphamide efficacy is attributable to depletion of 
all major leucocyte subsets,115 but a marked suppres-
sive effect on circulating lymphocytes, particularly B 
cells, was noted in several early studies.115–117 Sub-
sequent histological evidence of activated B cells in 
granulomata from patients with GPA,118 the role of B 
cells in antibody-mediated autoimmunity, and strong 
evidence for the pathogenicity of ANCA,104,119 all sup-
port an important role for B cells in the pathogenesis 
of ANCA-associated vasculitis and provide a rationale 
for targeted B-cell depletion (Figure 6). Furthermore, 
the side effects of cyclophosphamide, including an 
increased risk of malignancy, infection, and infertil-
ity,112 are a leading factor in the search for selective 
B-cell targeting.
B-Cell Depletion
The chimeric monoclonal antibody rituximab selectively 
depletes CD20 expressing B cells, and its development 
represents the most important therapeutic advance in 
ANCA-associated vasculitis since cyclophosphamide. 
The RAVE (Rituximab in ANCA-Associated Vasculitis)120 
and RITUXVAS (Rituximab Versus Cyclophosphamide in 
ANCA-Associated Vasculitis)121 trials established nonin-
feriority of rituximab to cyclophosphamide for remission 
induction of ANCA-associated vasculitis including for 
Figure 6. Targeting key mechanisms in the pathogenesis of antibody to neutrophil cytoplasmic antigens (ANCA) vasculitis.  
Cross-sectional diagram of a small artery depicting important pathogenic pathways of ANCA vasculitis. Upper left shows vessel structure in 
health; upper right shows the B-cell pathways; lower right shows the alternative complement pathway; lower left shows IL (interleukin)-5 
in eosinophilic granulomatosis with polyangiitis (EGPA). B-cell involvement in antibody production, T-cell costimulation, and B-cell activation 
contribute to production and binding of circulating ANCA to primed neutrophils expressing cytoplasmic antigens PR3 (proteinase-3; red 
circles) and MPO (myeloperoxidase; blue circles). ANCA binding triggers neutrophil degranulation with subsequent endothelial injury. B-cell 
depletion with rituximab, blocking costimulation with abatacept and inhibiting B-cell activation factors like BAFF (B-cell activating factor) with 
belimumab offers sophisticated inhibition of these pathways. Binding of complement protein C5a to its surface receptor on neutrophils leads 
to translocation of PR3 and MPO to the surface (neutrophil priming). Subsequent binding of circulating ANCA results in endothelial injury. 
Avacopan inhibits C5a binding. IL-5 promotes proliferation and migration of eosinophils out of bone marrow into the circulation. The precise 
steps that trigger subsequent eosinophil-mediated vascular injury are unclear but may involve ANCA. Targeting of IL-5 in EGPA is now possible 
using the monoclonal antibody mepolizumab. C5aR indicates C5a receptor; and MAC, membrane attack complex.
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those with organ and life-threatening presentations. At 
18 to 24 months of follow-up, rituximab induction with 
no additional maintenance therapy continued to demon-
strate noninferiority to cyclophosphamide induction with 
azathioprine maintenance in relation to rate of relapse, 
end-stage renal disease, and death.122,123 Importantly, 
the cumulative dose of glucocorticoids was no different 
between the 2 groups.122,123
Sustained B-cell depletion with a suppressed ANCA 
was associated with the lowest risk of relapse in RAVE 
and RITUXVAS.122,123 However, B-cell return occurred as 
early as 6 months after rituximab, and most patients had 
B-cell repopulation by 18 months post-dose.43 The MAIN-
RITSAN trial (Maintenance of Remission With Rituximab 
Versus Azathioprine for Newly-Diagnosed or Relapsing 
Eosinophilic Granulomatosis With Polyangiitis) explored 
whether, after cyclophosphamide induction, rituximab 
administered every 6 months for 18 months would offer 
greater protection against relapse versus standard-of-care 
azathioprine. Major relapse rates were significantly lower 
in the rituximab group (5% versus 29%; P=0.002).124 The 
benefits of rituximab extended for up to 5 years after enroll-
ment and were associated with a modest improvement in 
survival.125 However, tailoring maintenance treatment with 
rituximab according to the B-cell count or ANCA titer does 
not appear to be any better (or worse) than fixed-interval 
dosing in terms of efficacy and safety.126
What Next for B-Cell Depleting Therapy?
The optimal dosing interval for rituximab remains unclear. 
The RITAZAREM trial (Rituximab Versus Azathioprine as 
Therapy for Maintenance of Remission for Anti-Neutro-
phil Cytoplasm Antibody-Associated Vasculitis) is in prog-
ress and explores whether higher dose rituximab (1000 
mg) given more frequently (every 4 months for 5 doses) 
after rituximab induction for relapsing ANCA-associated 
vasculitis will provide greater protection compared with 
azathioprine.127 RAVE and RITUXVAS did not include 
patients with EGPA; so it is unclear whether the ben-
efits of B-cell depletion translate to this unique subtype 
of ANCA-associated vasculitis. However retrospective 
data suggest potential benefit of rituximab particularly in 
EGPA associated with circulating ANCA.128 The ongoing 
REOVAS (Rituximab in Eosinophilic Granulomatosis With 
Polyangiitis)129 and MAINRITSEG130 trials will shed light 
on the utility of this approach for induction and mainte-
nance therapy in EGPA, respectively.
Although recommended for remission induction and 
maintenance therapy in ANCA-associated vasculitis,111 
the available data do not support rituximab as being 
safer than other immunosuppressive agents. In clinical 
trials, the frequency of infections following rituximab was 
similar to cyclophosphamide, but this may be driven by 
concomitant glucocorticoid.122,123 Reactivation of latent 
hepatitis B infection,131 persisting hypogammaglobu-
linemia,132 and late-onset neutropenia133 are important 
side effects encountered with rituximab that contribute 
to morbidity. Furthermore, the chimeric structure of ritux-
imab is immunogenic and has been linked to the devel-
opment of infusion reactions and antichimeric antibodies 
that can limit its efficacy.134 The development of fully 
humanized anti-CD20 antibodies such as ofatumumab 
and obinutuzumab will hopefully address these issues.
However, the absence of consistent evidence show-
ing an increased risk of cancer following B-cell depletion 
is a potential benefit of this treatment option.135 Recent 
data from a single tertiary center reported a 3- and 
4-fold increased risk of cancer (mainly nonmelanoma-
tous skin cancer) with cyclophosphamide compared with 
the general population and patients receiving rituximab, 
respectively.136 Interestingly, the apparent protective 
effects of rituximab against risk of malignancy showed a 
dose-dependent relationship136—a concept supported by 
experimental data.137
B-Cell and T-Cell Costimulation and Depletion
The presence of granulomatous T-cell infiltrates in 
lung138 and renal biopsies139 along with impaired regula-
tory T-cell function in blood samples from patients with 
ANCA-associated vasculitis glomerulonephritis suggests 
a pathogenic role of T cells (Figure 6).140 Recent atten-
tion has focused on blocking T-cell costimulation by acti-
vated, antigen-presenting B cells with abatacept. In an 
open-label trial of 20 patients with a nonorgan threat-
ening relapse of GPA, abatacept led to disease remis-
sion in 80% and steroid discontinuation in ≈75% with a 
safety profile comparable to other treatment options.141 
An option for managing nonsevere relapse that permits 
steroid minimization would be of major clinical value in 
ANCA-associated vasculitis. The ongoing multicenter, 
randomized placebo-controlled ABROGATE trial (Abata-
cept for the Treatment of Relapsing, Non-Severe, Granu-
lomatosis With Polyangiitis) should define to what extent 
abatacept can achieve this.142
Depletion of both B and T cells can be achieved using 
alemtuzumab—a monoclonal antibody with specificity for 
CD52. CD52 is also expressed, in lower abundance, on 
monocytes/macrophages and eosinophils143; thus alem-
tuzumab exerts effects on a range of cellular components 
involved in the pathogenesis of ANCA-associated vascu-
litis. Retrospective data suggest a role for alemtuzumab 
as induction therapy for severe/refractory ANCA-asso-
ciated vasculitis but also reported high rates of infection 
and malignancy following its use.144 An open-label phase 
IV trial is in progress.145
B-Cell Survival and Relapse: Targeting BAFF
B-cell maturation is influenced by several cytokines 
including BAFF (B-cell activating factor; also known as 
BlyS [B-lymphocyte stimulator]) and is increasingly rec-
ognized as important in the pathogenesis of relapsing 
ANCA-associated vasculitis. BAFF signaling regulates 
the transition of naive B cells into memory B cells and 
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mature plasma cells.146 Increased BAFF expression 
is evident in patients with active vasculitis,147 and pre-
clinical data suggest that high BAFF concentrations can 
promote the survival of autoreactive B cells that under 
normal conditions would be deleted.148 These autoreac-
tive B cells can escape to peripheral lymphoid follicles 
where they may be less effectively depleted by anti-
CD20 therapies.110 In addition, B-cell depletion appears 
to increase concentrations of BAFF.149 Thus, B-cell 
depleting therapies in the context of high levels of BAFF 
may promote survival of autoreactive B cells that are able 
to trigger relapse during B-cell repopulation.
Belimumab is a fully humanized monoclonal antibody 
that prevents circulating BAFF binding to BAFF recep-
tors on B cells (Figure 6). In trials of patients with sys-
temic lupus erythematosus, this approach was effective 
in reducing relapse and glucocorticoid requirements.150 
In ANCA-associated vasculitis, the BREVAS study (Beli-
mumab in Remission of Vasculitis) attempted to compare 
belimumab to azathioprine for maintenance of remission 
in GPA and microscopic polyangiitis. However, the trial 
was stopped early because of suboptimal recruitment 
with no concrete evidence of improved benefit. Combin-
ing BAFF targeting with other anti–B-cell therapies may 
offer additional benefit by preventing autoreactive B-cell 
escape and enabling more complete B-cell depletion.
Alternative Complement Pathway: Targeting  
C5a Receptors
The complement system is a central mediator of antibody-
mediated immune responses.151 C5 is a potent effector 
protein in this pathway, exerting its effects through its 
cleavage products C5a, a powerful chemoattractant, and 
C5b, part of the membrane attack complex that lyses 
target cells.152 Activation of the alternative complement 
pathway is evident in ANCA-associated vasculitis. Kid-
ney biopsies from patients with ANCA-associated glo-
merulonephritis show deposition of alternative pathway 
components in active glomerular lesions.153 In addition, 
high circulating levels of C3, C5a, and soluble C5b-9 
(membrane attack complex) have been found in patients 
with active vasculitis, which subsequently fall in disease 
remission.154 In vitro, C5a primes neutrophils for ANCA-
induced degranulation that leads to endothelial injury 
(Figure 6).155 Finally, in murine MPO models, knocking 
out C5a and C5aR (C5a receptor) is protective against 
the development of necrotizing glomerulonephritis, as is 
pharmacological blockade of C5aR.156,157
Clinical trial evidence of the utility of the C5a receptor 
inhibition with avacopan has recently emerged.158 Sixty-
seven patients with ANCA-associated vasculitis were 
randomized to either high-dose glucocorticoids, avaco-
pan plus low-dose glucocorticoids, or avacopan alone 
alongside cyclophosphamide or rituximab induction. The 
primary end point of treatment response at 12 weeks 
(a 50% reduction from baseline in the Birmingham 
Vasculitis Activity Score) occurred in 86% of the ava-
copan/glucocorticoid and 81% of the avacopan-alone 
groups, compared with 70% in the glucocorticoid group 
(P=0.002 and P=0.01, respectively). Markers of renal 
injury and inflammation fell across all groups, but reduc-
tions occurred earlier and were of a greater magnitude 
with avacopan. Serious adverse effects such as psychi-
atric disturbances and new-onset diabetes mellitus were 
more common in the high-dose glucocorticoid group.158 
These promising results suggest that glucocorticoid-
free remission induction in ANCA-associated vasculitis 
is achievable with novel targeted therapies. The ongo-
ing larger and of longer duration phase 3 ADVOCATE 
trial (A Phase 3 Clinical Trial of CCX168 [Avacopan] in 
Patients With ANCA-Associated Vasculitis) will explore 
this further.159
Eosinophils in EGPA: Targeting IL-5
The immunopathology of EGPA is unique: it often lacks 
circulating ANCA, and the role of B cells and associated 
cytokines such as BAFF is unclear.160 Indeed, ANCA-
negative EGPA and ANCA-positive EGPA (predominantly 
because of circulating MPO ANCA) are increasingly rec-
ognized as separate diseases with distinct genetic asso-
ciations and clinical features.161 ANCA-negative EGPA 
has associations with single-nucleotide polymorphisms 
within the IL-10 promoter gene,162 whereas ANCA-pos-
itive forms are frequently associated with HLA-DRB1 
and 7 (HLA class II histocompatibility antigen, DRB1 
beta chain).163 These genetics may explain, in part, the 
differences in clinical phenotype as cardiac involvement 
is much more common in ANCA-negative patients but 
renal and nerve involvement are more frequent in those 
with circulating ANCA.164 In addition, a representative 
animal model does not exist, and patients with EGPA 
are underrepresented in the major clinical trials of ANCA 
vasculitis, thus they may not derive the same benefits 
from treatments with proven efficacy for other subtypes. 
A central feature of EGPA is a tissue and blood eosino-
philia. IL-5 is a key mediator of this and stimulates eosin-
ophil proliferation, survival, and migration into vessels and 
tissues (Figure 6).160 Clinical studies have found high 
IL-5 concentrations in bronchoalveolar lavage samples 
of patients with active EGPA, which stimulates broncho-
spasm and bronchial eosinophilic infiltration.165
Mepolizumab is a fully humanized recombinant mono-
clonal antibody with specificity for IL-5. Small, open-label 
studies indicated the potential of mepolizumab to deplete 
circulating eosinophils, induce remission, and allow ste-
roid taper in EGPA.166,167 A recent randomized, double-
blinded trial assigned 136 patients with refractory or 
relapsing EGPA to monthly mepolizumab or placebo.168 
After 52 weeks, patients in the mepolizumab arm spent 
significantly more time in remission, with 28% spend-
ing >24 weeks in remission compared with 3% in the 
placebo group.168 Serious adverse events were more 
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frequent in the placebo arm, and mepolizumab was well 
tolerated. The relapse rate was high: 47% and 82% in 
the mepolizumab and standard-of-care arms, respec-
tively. This may reflect the inclusion of patients with long-
standing disease and a high tissue eosinophil burden 
that is resistant to IL-5 blockade.168 Long-term treatment 
with mepolizumab may be necessary as relapse occurred 
rapidly following discontinuation. However, mepolizumab 
is an important advance in EGPA and received Food and 
Drug Administration approval in late 2017.
Imaging in ANCA-Associated Vasculitis
Despite validated tools such as Birmingham Vasculitis 
Activity Score, assessing disease activity in patients on 
treatment remains challenging in ANCA-associated vas-
culitis. While interval biopsies to assess disease activity 
may be more feasible compared with GCA, this approach 
is impractical. Thus, a noninvasive means of detecting small 
vessel inflammation would be equally valuable in SVV.
PET in ANCA-Associated Vasculitis
PET may provide additional information about disease 
activity in patients with lung or sinonasal involvement, 
typically seen in GPA. Standard CT offers coarse struc-
tural metrics of disease activity such as a reduction in 
size of nodules, masses, or mucosal thickening but often 
these do not fully resolve.169 In addition, patients with 
GPA often report symptoms suggestive of disease activ-
ity170 but lack a robust clinical measure of this. There 
are no prospective studies of the use of 18F-FDG PET 
to monitor disease activity in ANCA-associated vascu-
litis, but retrospective studies have reported increased 
18F-FDG uptake in clinically affected organs.171 Persis-
tent 18F-FDG uptake on follow-up imaging was seen in 
patients with elevated disease activity scores suggest-
ing PET could at least match current tools.171 Prospec-
tive studies are needed to explore whether this imaging 
modality can identify currently unidentifiable and subclin-
ical smoldering disease.
FUTURE DIRECTIONS
New Indications for Established Drugs
Targeting VSMCs: the Endothelin System in LVV
Suppressing remodeling due to vasculitis may be done 
by targeting pathways beyond leucocyte-IL signaling. 
ET-1 (endothelin-1) is the most potent endogenous 
vasoconstrictor in man and is largely produced by endo-
thelial cells.172 ET-1 exerts its effects through 2 recep-
tors: the ETA (endothelin-A) and the ETB (endothelin-B) 
receptor.172 Within the vasculature, ETA receptors are 
located on VSMC, whereas ETB receptors are expressed 
on both VSMC and endothelial cells.173 ETA receptor acti-
vation is generally associated with pathological effects 
such as vasoconstriction, inflammation, and atheroscle-
rosis,173 whereas ETB receptors mediate vasodilation and 
clearance of ET-1, although VSMC ETB receptors do pro-
mote vasoconstriction.173 Temporal artery biopsies from 
patients with GCA have revealed increased ET-1 peptide, 
ETA, and ETB, expression in arteritic lesions.
174,175 Addi-
tionally, a study of inflamed vessel explants from patients 
with GCA showed that ET-1 stimulated VSMC migration 
in vitro (Figure 1).175 Furthermore, this outgrowth was 
inhibited by pretreatment with an ETB antagonist and to 
a lesser extent by an ETA antagonist.
175
Pure ETB antagonism is unlikely to be translatable to 
clinical settings given the potential deleterious effects of 
unopposed systemic ETA activation. Ambrisentan, bosen-
tan, and macitentan are dual ETA/B antagonists that are 
currently approved for use in pulmonary arterial hyperten-
sion.176 Pulmonary arterial hypertension is characterized by 
florid VSMC proliferation in pulmonary vessels driven by an 
activated ET system, which can be ameliorated by ETA/B 
antagonism.177 A similar role of ET-1 in vascular remodeling 
in LVV suggests a potential novel therapeutic indication for 
this drug class that is already available in the clinic. There 
are no registered clinical trials of ET receptor antagonism 
in LVV. However, ET antagonism has emerged as an impor-
tant potential therapeutic strategy in chronic kidney dis-
ease with a recent large clinical trial demonstrating both 
efficacy and safety in slowing the loss of kidney function.178
Structural Imaging
Interrogating the Retinal Microvasculature
The eye acts as a window to the systemic and regional 
microvasculature. Systemic diseases such as hyperten-
sion and diabetes mellitus have profound effects on 
retinal microvessels as demonstrated by structural and 
functional retinal imaging.179,180 Retinal optical coherence 
tomography captures the chorioretinal microcirculation, in 
particular, the highly vascularized choroid, with near-his-
tological resolution.181 In systemic disease, optical coher-
ence tomography has revealed retinal vessel remodeling 
and chorioretinal thinning in hypertension, diabetes mel-
litus, and chronic kidney disease.182–184 Additionally, pre-
clinical and clinical optical coherence tomography have 
linked retinal microvascular pathology to circulating and 
histological markers of injury within the kidney.184 We 
have shown that the highly vascularized choroid thins with 
increasing levels of systemic inflammation184 potentially 
indicative of microvascular injury. In addition, in patients 
with ANCA-associated glomerulonephritis, we found that 
the severity of choroidal thinning mirrored the degree of 
vascular inflammation as represented by the number of 
glomerular crescents and focal necrotizing lesions on 
renal histology.184 Studies to explore whether metrics are 
modified by treatment will clarify these associations fur-
ther. The strong association between GCA and ischemic 
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ocular complications such as arteritic ischemic optic neu-
ropathy and retinal ischemia from choroidal hypoperfu-
sion suggests optical coherence tomography may offer a 
novel means of identifying patients at risk of impending 
ischemic ocular complications.185
Novel MR/MRA Techniques for LVV
Improving MR imaging specificity for disease activ-
ity assessment in LVV is an important area for further 
research. Diffusion weighted imaging sequences detect 
the restriction of intracellular proton movement, typically 
in the context of cytotoxic edema following acute isch-
emia. Diffusion weighted imaging sequences are well 
established in MR imaging of acute stroke and highly 
sensitive for the detection of early infarcts. A recent 
proof-of-concept study hypothesized that the intense cel-
lular infiltrate of LVV may also restrict proton movement 
within the vessel wall and thus be detectable using dif-
fusion weighted imaging.186 In combination with 18F-FDG 
PET, diffusion weighted imaging was able to differenti-
ate between overtly active, smoldering, inactive GCA and 
health.186 Mural contrast enhancement as shown by con-
ventional gadolinium-based contrast agents is assumed 
to represent active vessel inflammation but can also be 
seen in inactive disease.187 Newer contrast agents such 
as gadofosveset trisodium are better retained in the 
intravascular compartment and have shown promise in 
differentiating between active and inactive mural inflam-
mation in a small study of TA.188 Both these techniques 
require further study to better define their potential utility.
Molecular Imaging
18F-FDG reliably reports vessel wall macrophage hyper-
metabolism, but this is prominent in atherosclerosis, as 
well as LVV, and discriminating between these patholo-
gies is challenging.189 The pattern of 18F-FDG uptake in 
atheromatous disease is often focal and related to the 
intima unlike the linear, diffuse medial uptake in vascu-
litis.190 Furthermore, in untreated LVV, 18F-FDG uptake 
is intense (described as greater than liver uptake when 
using visual assessment scoring), whereas low-grade 
uptake (less than liver uptake) is suggestive of athero-
sclerosis.190 Large arterial calcification identified by hybrid 
PET/CT may aid identification of atherosclerosis over 
LVV.190 However, the lack of specificity of 18F-FDG limits its 
use in assessing disease activity in patients on treatment 
where low-grade subclinical vasculitis and atheroma may 
coexist. The development of PET tracers to identify differ-
ential polarization of macrophages or immune checkpoint 
activity may offer a more precise means of assessing dis-
ease activity, as well as differentiating between vasculitic 
and atherosclerotic forms of vascular inflammation.
Imaging Macrophage Activation
Activated macrophages express a range of specific recep-
tors that can be targeted by radiotracer ligands. TSPO 
(translocator protein; also known as peripheral benzodi-
azepine receptor) is expressed on mitochondria of phago-
cytic cells of mononuclear lineage. The ligand PK11195 
has specificity for TSPO with binding confirming the pres-
ence of activated macrophages in atheromatous carotid 
endarterectomy specimens.191 PET with 11C-PK11195 
has been used widely in neuroinflammatory disease192 
because of increased TSPO expression in microglia, but 
data in LVV are limited. A small study suggested the poten-
tial for 11C-PK11195 to track disease activity in LVV, 
as well as differentiate between quiescent and unstable 
carotid atheroma, but no larger studies have followed.193
Gallium-68-labeled [1,4,7,10-tetraazacyclododecane-
N,N′,N″,N‴-tetraacetic acid]-D-Phe1, Tyr3-octreotate 
(Ga-DOTATATE) is a PET tracer with specificity for the 
SST-2 (somatostatin receptor subtype 2) expressed by 
macrophages.194,195 Recent data have demonstrated 
markedly increased SST-2 expression on activated mac-
rophages with a proinflammatory M1 phenotype com-
pared with both unstimulated and anti-inflammatory M2 
macrophages.196 In addition, Ga-DOTATATE uptake by 
carotid atheroma in endarterectomy specimens strongly 
correlated with macrophage burden and SST-2 gene 
expression, while uptake on clinical PET-CT reliably iden-
tified culprit carotid and coronary lesions.196 Moreover, 
Ga-DOTATATE was better than 18F-FDG at identifying 
high-risk coronary plaques, and uptake was more discrete 
allowing precise anatomic description of uptake.196 The 
power of Ga-DOTATATE to reflect macrophage behav-
ior has exciting translational potential for LVV. Studies to 
assess SST-2 expression and Ga-DOTATATE uptake in 
temporal artery biopsy specimens with tracer uptake on 
concurrent PET imaging before and after immunosup-
pression are needed to fully evaluate its potential in LVV.
Imaging Immune Checkpoints
The PD-1 (programmed death-1)/PD-L1 (programmed 
death ligand-1) system is an immune checkpoint path-
way involved in the regulation of T-cell responses to anti-
gens.197 Under normal conditions, interaction of PD-L1 
with PD-1 leads to controlled suppression of exuberant 
T-cell activation by promoting T-cell apoptosis.197 Over-
activity of this checkpoint leads to impaired T-cell tumor 
surveillance, and therapeutic inhibition of the PD-1/
PD-L1 checkpoint has led to improved patient outcomes 
in oncology.198
PD-L1 expression appears divergent in different 
forms of vascular inflammation with downregulation in 
LVV and overexpression in atherosclerosis.199 In LVV, 
this downregulation allows unopposed T-cell activation 
and leads to the classic florid inflammatory response.200 
In atherosclerosis, sustained PD-L1 overexpression 
appears to impair T-cell activation and clonal expan-
sion, which normally have protective roles in response to 
plaque inflammation.201 PET tracers that bind to PD-1/
PD-L1 and report its activity to guide anticancer therapy 
D
ow
nloaded from
 http://ahajournals.org by on August 6, 2019
AT
VB
 IN
 F
OC
US
 - 
VB
Farrah et al Novel Management of Vasculitis
August 2019 Arterioscler Thromb Vasc Biol. 2019;39:1520–1541. DOI: 10.1161/ATVBAHA.118.3109571536
have now been evaluated in clinical studies with encour-
aging results.202,203 With further development, scientists 
may be able to precisely and noninvasively define the 
nature of vessel inflammation and monitor response 
to treatment through so-called immuno-PET. Further 
detailed characterization of these pathways, including 
changes after treatment, is necessary, but PD-1/PD-L1 
targeting offers an exciting novel imaging and therapeu-
tic frontier in vasculitis.
Conclusions
Major advances in the management of systemic vascu-
litis have taken place over the last decade. Advances in 
pathogenesis and imaging technology have translated 
into safer, more effective treatments and less invasive 
diagnostic and monitoring methods. Despite the success 
of blocking IL-6 and T-cell activation in GCA, relapse 
rates and glucocorticoid use remain high suggesting 
further refinement is needed. This is particularly true for 
TA where these novel agents appear to offer little ben-
efit. The discovery of mutations in ADA2 in familial PAN 
syndromes may yield further insights into classical PAN 
and treatment options including TNFα blockade. ANCA-
associated vasculitis has seen landmark improvements 
in clinical outcomes by targeting B cells. Recent trials of 
therapies that target B-cell activation, complement and 
IL-5 provide encouraging evidence of better outcomes for 
these patients. In addition, imaging has emerged to take 
a central role in vasculitis with ultrasound, CT, MRA, and 
PET each demonstrating unique strengths and limitations 
for diagnosis of LVV. Robust imaging-based methods of 
assessing disease activity remain elusive because of a 
discordance with clinical biomarkers, lack of comparable 
histology in many cases, and confounding by atheroscle-
rosis. The advent of novel tracers and immuno-PET that 
allow noninvasive tracking of immune checkpoint activity 
may provide a solution. Further refinement of both treat-
ments and imaging technology will hopefully allow clini-
cians to offer patients with vasculitis noninvasive disease 
monitoring, more precise treatments, and truly individual-
ized patient management in the near term.
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